Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jun 30;6(6):CD009567.
doi: 10.1002/14651858.CD009567.pub2.

Interventions for treating acute high altitude illness

Daniel Simancas-Racines  1 , Ingrid Arevalo-Rodriguez, Dimelza Osorio, Juan Va Franco, Yihan Xu, Ricardo Hidalgo
Affiliations
Meta-Analysis

Interventions for treating acute high altitude illness

Daniel Simancas-Racines et al. Cochrane Database Syst Rev. .

Abstract

Background: Acute high altitude illness is defined as a group of cerebral and pulmonary syndromes that can occur during travel to high altitudes. It is more common above 2500 metres, but can be seen at lower elevations, especially in susceptible people. Acute high altitude illness includes a wide spectrum of syndromes defined under the terms 'acute mountain sickness' (AMS), 'high altitude cerebral oedema' and 'high altitude pulmonary oedema'. There are several interventions available to treat this condition, both pharmacological and non-pharmacological; however, there is a great uncertainty regarding their benefits and harms.

Objectives: To assess the clinical effectiveness, and safety of interventions (non-pharmacological and pharmacological), as monotherapy or in any combination, for treating acute high altitude illness.

Search methods: We searched CENTRAL, MEDLINE, Embase, LILACS, ISI Web of Science, CINAHL, Wanfang database and the World Health Organization International Clinical Trials Registry Platform for ongoing studies on 10 August 2017. We did not apply any language restriction.

Selection criteria: We included randomized controlled trials evaluating the effects of pharmacological and non-pharmacological interventions for individuals suffering from acute high altitude illness: acute mountain sickness, high altitude pulmonary oedema or high altitude cerebral oedema.

Data collection and analysis: Two review authors independently assessed the eligibility of study reports, the risk of bias for each and performed the data extraction. We resolved disagreements through discussion with a third author. We assessed the quality of evidence with GRADE.

Main results: We included 13 studies enrolling a total of 468 participants. We identified two ongoing studies. All studies included adults, and two studies included both teenagers and adults. The 13 studies took place in high altitude areas, mostly in the European Alps. Twelve studies included participants with acute mountain sickness, and one study included participants with high altitude pulmonary oedema. Follow-up was usually less than one day. We downgraded the quality of the evidence in most cases due to risk of bias and imprecision. We report results for the main comparisons as follows.Non-pharmacological interventions (3 studies, 124 participants)All-cause mortality and complete relief of AMS symptoms were not reported in the three included trials. One study in 64 participants found that a simulated descent of 193 millibars versus 20 millibars may reduce the average of symptoms to 2.5 vs 3.1 units after 12 hours of treatment (clinical score ranged from 0 to 11 ‒ worse; reduction of 0.6 points on average with the intervention; low quality of evidence). In addition, no complications were found with use of hyperbaric chambers versus supplementary oxygen (one study; 29 participants; low-quality evidence).Pharmacological interventions (11 trials, 375 participants)All-cause mortality was not reported in the 11 included trials. One trial found a greater proportion of participants with complete relief of AMS symptoms after 12 and 16 hours when dexamethasone was administered in comparison with placebo (47.1% versus 0%, respectively; one study; 35 participants; low quality of evidence). Likewise, when acetazolamide was compared with placebo, the effects on symptom severity was uncertain (standardized mean difference (SMD) -1.15, 95% CI -2.56 to 0.27; 2 studies, 25 participants; low-quality evidence). One trial of dexamethasone in comparison with placebo in 35 participants found a reduction in symptom severity (difference on change in the AMS score: 3.7 units reported by authors; moderate quality of evidence). The effects from two additional trials comparing gabapentin with placebo and magnesium with placebo on symptom severity at the end of treatment were uncertain. For gabapentin versus placebo: mean visual analogue scale (VAS) score of 2.92 versus 4.75, respectively; 24 participants; low quality of evidence. For magnesium versus placebo: mean scores of 9 and 10.3 units, respectively; 25 participants; low quality of evidence). The trials did not find adverse events from either treatment (low quality of evidence). One trial comparing magnesium sulphate versus placebo found that flushing was a frequent event in the magnesium sulphate arm (percentage of flushing: 75% versus 7.7%, respectively; one study; 25 participants; low quality of evidence).

Authors' conclusions: There is limited available evidence to determine the effects of non-pharmacological and pharmacological interventions in treating acute high altitude illness. Low-quality evidence suggests that dexamethasone and acetazolamide might reduce AMS score compared to placebo. However, the clinical benefits and harms related to these potential interventions remain unclear. Overall, the evidence is of limited practical significance in the clinical field. High-quality research in this field is needed, since most trials were poorly conducted and reported.

PubMed Disclaimer

Conflict of interest statement

Daniel Simancas‐Racines: no conflict of interest.

Dimelza Osorio: no conflict of interest.

Juan VA Franco: no conflict of interest.

Ingrid Arevalo‐Rodriguez: no conflict of interest.

Yihan Xu: no conflict of interest.

Ricardo Hidalgo: no conflict of interest.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009567

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bärtsch 1990 {published data only}
    1. Bärtsch P, Baumgartner RW, Waber U, Maggiorini M, Oelz O. Comparison of carbon‐dioxide‐enriched, oxygen‐enriched, and normal air in treatment of acute mountain sickness. Lancet 1990;336(8718):772‐5. [PUBMED: 1976147] - PubMed
Bärtsch 1993 {published data only}
    1. Bärtsch P, Merki B, Hofstetter D, Maggiorini M, Kayser B, Oelz O. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993;306(6885):1098‐101. [PUBMED: 8495155] - PMC - PubMed
Dumont 2004 {published data only}
    1. Dumont L, Lysakowski C, Tramèr MR, Junod JD, Mardirosoff C, Tassonyi E, et al. Magnesium for the prevention and treatment of acute mountain sickness. Clinical Science 2004;106(3):269‐77. [PUBMED: 14572305] - PubMed
Ferrazzini 1987 {published data only}
    1. Ferrazzini G, Maggiorini M, Kriemler S, Bärtsch P, Oelz O. Successful treatment of acute mountain sickness with dexamethasone. BMJ (Clinical Research Ed.) 1987;294(6584):1380‐2. [PUBMED: 3109663] - PMC - PubMed
Grissom 1992 {published data only}
    1. Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Annals of Internal Medicine 1992;116(6):461‐5. [PUBMED: 1739236] - PubMed
Harris 2003 {published data only}
    1. Harris NS, Wenzel RP, Thomas SH. High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. Journal of Emergency Medicine 2003;24(4):383‐7. [PUBMED: 12745039] - PubMed
Jafarian 2007a {published data only}
    1. Jafarian S, Gorouhi F, Salimi S, Lotfi J. Low‐dose gabapentin in treatment of high‐altitude headache. Cephalalgia 2007;27(11):1274‐7. [PUBMED: 17692105] - PubMed
Kasic 1991 {published data only}
    1. Kasic JF, Yaron M, Nicholas RA, Lickteig JA, Roach R. Treatment of acute mountain sickness: hyperbaric versus oxygen therapy. Annals of Emergency Medicine 1991;20(10):1109‐12. [PUBMED: 1928883] - PubMed
Keller 1995 {published data only}
    1. Keller HR, Maggiorini M, Bärtsch P, Oelz O. Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995;310(6989):1232‐5. [PUBMED: 7767194] - PMC - PubMed
Li 2006 {published data only}
    1. Li S, Zheng B, He Y, Wang H, Li, Qu T. The effect of the therapy on acute high altitude disease by inhaling nitrogen monoxidum air balanced in plateau. Journal of Chinese Physician 2006;8(12):1631‐3.
Utiger 2002 {published data only}
    1. Utiger D, Eichenberger U, Bernasch D, Baumgartner RW, Bärtsch P. Transient minor improvement of high altitude headache by sumatriptan. High Altitude Medicine and Biology 2002;3(4):387‐93. [PUBMED: 12631424] - PubMed
Wang 1998 {published data only}
    1. Wang W, Zhang X, Ma Y. [Low‐concentration nitrous oxide inhalation in the treatment of high‐altitude pulmonary edema]. Chinese Journal of Tuberculosis and Respiratory Diseases 1998;21(4):212‐4. [PUBMED: 11326965] - PubMed
Wright 1994 {published data only}
    1. Wright AD, Winterborn MH, Forster PJ, Delamere JP, Harrison GL, Bradwell AR. Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness. Journal of Wilderness Medicine 1994;5(1):49‐55. [DOI: 10.1580/0953-9859-5.1.49] - DOI

References to studies excluded from this review

Anand 1998 {published data only}
    1. Anand IS, Prasad BA, Chugh SS, Rao KR, Cornfield DN, Milla CE, et al. Effects of inhaled nitric oxide and oxygen in high‐altitude pulmonary edema. Circulation 1998;98(22):2441‐5. [PUBMED: 9832490] - PubMed
Bärtsch 1992 {published data only}
    1. Bärtsch P. Treatment of high altitude diseases without drugs. International Journal of Sports Medicine 1992;13 Suppl 1:S71‐4. [PUBMED: 1483799] - PubMed
Bärtsch 1994 {published data only}
    1. Bärtsch P, Maggi S, Kleger GR, Ballmer PE, Baumgartner RW. Sumatriptan for high‐altitude headache. Lancet 1994; Vol. 344, issue 8934:1445. [PUBMED: 7968111] - PubMed
Bates 2007 {published data only}
    1. Bates MG, Thompson AA, Baillie JK. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Current Opinion in Investigational Drugs (London, England : 2000) 2007;8(3):226‐31. [PUBMED: 17408118] - PubMed
Benedetti 2015 {published data only}
    1. Benedetti F, Durando J, Giudetti L, Pampallona A, Vighetti S. High‐altitude headache: the effects of real vs sham oxygen administration. Pain 2015;156(11):2326‐36. [PUBMED: 26164587] - PubMed
Bradwell 1988 {published data only}
    1. Bradwell AR, Winterborn M, Wright AD, Forster PE, Dykes PW. Acetazolamide treatment of acute mountain sickness [abstract]. Clinical Science 1988;74(Suppl 18):62P. [CENTRAL: CN‐00258335]
Broome 1994 {published data only}
    1. Broome JR, Stoneham MD, Beeley JM, Milledge JS, Hughes AS. High altitude headache: treatment with ibuprofen. Aviation, Space, and Environmental Medicine 1994;65(1):19‐20. [PUBMED: 8117220] - PubMed
Brown 1977 {published data only}
    1. Spironolactone in acute mountain sickness. Lancet (London, England) 1977; Vol. 1, issue 8016:855. [PUBMED: 67358] - PubMed
Burtscher 1995 {published data only}
    1. Burtscher M, Likar R, Nachbauer W, Schaffert W, Philadelphy M. Ibuprofen versus sumatriptan for high‐altitude headache. Lancet (London, England) 1995; Vol. 346, issue 8969:254‐5. [PUBMED: 7616830] - PubMed
Deshwal 2012 {published data only}
    1. Deshwal R, Iqbal M, Basnet S. Nifedipine for the treatment of high altitude pulmonary edema. Wilderness & Environmental Medicine 2012;23(1):7‐10. [PUBMED: 22441082] - PubMed
Fagenholz 2007 {published data only}
    1. Fagenholz PJ, Gutman JA, Murray AF, Harris NS. Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Altitude Medicine & Biology 2007;8(2):139‐46. [PUBMED: 17584008] - PubMed
Forster 1982 {published data only}
    1. Forster P. Methazolamide in acute mountain sickness. Lancet (London, England) 1982; Vol. 1, issue 8283:1254. [PUBMED: 6123014] - PubMed
Forwand 1968 {published data only}
    1. Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. New England Journal of Medicine 1968;279(16):839‐45. [PUBMED: 4877992] - PubMed
Levine 1989 {published data only}
    1. Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G. Dexamethasone in the treatment of acute mountain sickness. New England Journal of Medicine 1989;321(25):1707‐13. [PUBMED: 2687688] - PubMed
Li 2010 {published data only}
    1. Li SZ, Zheng BH, Yan CC, Wang YL, Zeng JB, Chen B, et al. Four therapeutic regimens for high altitude pulmonary edema: result comparison and preliminary study of standardized treatment. Medical Journal of National Defending Forces in Southwest China 2010;20(7):771‐4.
Maggiorini 1995 {published data only}
    1. Maggiorini M, Merki B, Pallavicini E, Bärtsch P, Oelz O. Acetazolamide and almitrin in the treatment of acute mountain sickness [Acetozolamid und Almitrin bei Behandlung der akuten Bergkrankheit]. Schweizerische Medizinische Wochenschrift 1995;125(Suppl 69):55. [CENTRAL: CN‐00307575]
Meehan 1986 {published data only}
    1. Meehan RT, Cymerman A, Rock P, Fulco CS, Hoffman J, Abernathy C, et al. The effect of naproxen on acute mountain sickness and vascular responses to hypoxia. American Journal of the Medical Sciences 1986;292(1):15‐20. [PUBMED: 3521277] - PubMed
Oelz 1989 {published data only}
    1. Oelz O, Maggiorini M, Ritter M, Waber U, Jenni R, Vock P, et al. Nifedipine for high altitude pulmonary oedema. Lancet 1989;2(8674):1241‐4. [PUBMED: 2573760] - PubMed
Oelz 1992 {published data only}
    1. Oelz O, Maggiorini M, Ritter M, Noti C, Waber U, Vock P, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. International Journal of Sports Medicine 1992;13 Suppl 1:S65‐8. [PUBMED: 1483797] - PubMed
Roggla 2001 {published data only}
    1. Roggla G, Domej W, Roggla M. Does theophylline really improve acute mountain sickness?. European Respiratory Journal 2001; Vol. 17, issue 3:575. [PUBMED: 11405540] - PubMed
Wright 1988 {published data only}
    1. Wright AD, Bradwell AR. Cerebral blood flow in acute mountain sickness and treatment with acetazolamide [abstract]. Clinical Science 1988;74(Suppl 18):1. [CENTRAL: CN‐00258251]
Yan 2010 {published data only}
    1. Yan Ch, Li S, Wang Y, Zheng B, Zheng J, Chen B, et al. Three therapeutic regimens for high altitude cerebral edema:result comparison and preliminary study of standardized treatment [高原脑水肿不同治疗方案的疗效比较及其规范化治疗初步探讨]. Medical Journal of National Defending Forces in Southwest China 2010;20(7):774‐7.
Yanamandra 2016 {published data only}
    1. Yanamandra U, Nair V, Singh S, Gupta A, Mulajkar D, Yanamandra S, et al. Managing high‐altitude pulmonary edema with oxygen alone: results of a randomized controlled trial. High Altitude Medicine and Biology 2016;17(4):294‐9. [PUBMED: 27906598] - PubMed
Zhang 2012 {published data only}
    1. Zhang XF, Ma SQ, Wu SZ, Yang ZP, Chen Q. [Bundle program of treatment for acute severe type high altitude disease]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue = Chinese Critical Care Medicine 2012;24(7):415‐8. [PUBMED: 22748458] - PubMed

References to ongoing studies

ChiCTR‐TRC‐13003298 {published data only}
    1. ChiCTR‐TRC‐13003298. Oral trimetazidine for reducing the symptoms of acute mountain sickness and improving exercise performance. www.chictr.org.cn/showprojen.aspx?proj=6261 first received 29 June 2013.
NCT01522326 {unpublished data only}
    1. NCT01522326. Comparison of metoclopramide and ibuprofen for the treatment of acute mountain sickness. clinicaltrials.gov/ct2/show/NCT01522326 first received 31 January 2012.

Additional references

Adams 2004
    1. Adams J. Ginkgo biloba and acetazolamide for acute mountain sickness: exclusion of high risk, low status groups perpetuates discrimination and inequalities. BMJ (Clinical Research Ed.) 2004;329(7458):171; author reply 172. [PUBMED: 15258082] - PMC - PubMed
Austin 1998
    1. Austin D. Gammow bag for acute mountain sickness. Lancet 1998;351(9118):1815. [PUBMED: 9635981] - PubMed
Bailey 2009
    1. Bailey DM, Bärtsch P, Knauth M, Baumgartner RW. Emerging concepts in acute mountain sickness and high‐altitude cerebral edema: from the molecular to the morphological. Cellular and Molecular Life Sciences 2009;66(22):3583‐94. [PUBMED: 19763397] - PMC - PubMed
Basnyat 2003
    1. Basnyat B, Murdoch DR. High‐altitude illness. Lancet 2003;361(9373):1967‐74. [PUBMED: 12801752] - PubMed
Blitzer 1996
    1. Blitzer ML, Loh E, Roddy MA, Stamler JS, Creager MA. Endothelium‐derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. Journal of the American College of Cardiology 1996;28(3):591‐6. [PUBMED: 8772744] - PubMed
Burtscher 2001
    1. Burtscher M, Likar R, Nachbauer W, Philadelphy M, Puhringer R, Lammle T. Effects of aspirin during exercise on the incidence of high‐altitude headache: a randomized, double‐blind, placebo‐controlled trial. Headache 2001;41(6):542‐5. [PUBMED: 11437888] - PubMed
Bärtsch 2004
    1. Bärtsch P, Bailey DM, Berger MM, Knauth M, Baumgartner RW. Acute mountain sickness: controversies and advances. High Altitude Medicine & Biology 2004;5(2):110‐24. [PUBMED: 15265333] - PubMed
Bärtsch 2013
    1. Bärtsch P, Swenson ER. Acute high‐altitude illnesses. New England Journal of Medicine 2013;369(17):1666‐7. [PUBMED: 24152275] - PubMed
Canoui‐Poitrine 2014
    1. Canoui‐Poitrine F, Veerabudun K, Larmignat P, Letournel M, Bastuji‐Garin S, Richalet JP. Risk prediction score for severe high altitude illness: a cohort study. PloS One 2014;9(7):e100642. [PUBMED: 25068815] - PMC - PubMed
CATMAT 2007
    1. CATMAT. Statement on high‐altitude illnesses. An Advisory Committee Statement (ACS). Committee to Advise on Tropical Medicine and Travel (CATMAT). Canada Communicable Disease Report = Releve des Maladies Transmissibles au Canada 2007;33(ACS‐5):1‐20. [PUBMED: 17520777] - PubMed
CDC Yellow Book 2016
    1. Centers for Disease Control and Prevention. CDC Health Information for International Travel 2016. New York: Oxford University Press, 2016.
Cheng 2006
    1. Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. Journal of Pharmacological Sciences 2006;100(5):471‐86. [PUBMED: 16474201] - PubMed
Chinese Medical Association 1996
    1. Third Ad Hoc Committee on High Altitude Illnesses of Chinese Medical Association. Consensus statement for the criteria for the denomination, classification and diagnosis of high altitude illnesses in China. Tibetan Medicine Journal 1996;17:1‐3.
Dehnert 2010
    1. Dehnert C, Bärtsch P. Can patients with coronary heart disease go to high altitude?. High Altitude Medicine & Biology 2010;11(3):183‐8. [PUBMED: 20919884] - PubMed
Eide 2012
    1. Eide RP 3rd, Asplund CA. Altitude illness: update on prevention and treatment. Current Sports Medicine Reports 2012;11(3):124‐30. [PUBMED: 22580489] - PubMed
Elphick 2004
    1. Elphick HL, Elphick DA. Ginkgo biloba and acetazolamide for acute mountain sickness: bias in participants may underestimate effectiveness of agents. BMJ (Clinical research edition) 2004; Vol. 329, issue 7458:172; author reply 172. [PUBMED: 15258084] - PMC - PubMed
Fisher 2000
    1. Fischer R, Lang SM, Steiner U, Toepfer M, Hautmann H, Pongratz H, et al. Theophylline improves acute mountain sickness. European Respiratory Journal 2000;15(1):123‐7. [PUBMED: 10678632] - PubMed
Freeman 2004
    1. Freeman K, Shalit M, Stroh G. Use of the Gamow bag by EMT‐basic park rangers for treatment of high‐altitude pulmonary edema and high‐altitude cerebral edema. Wilderness & Environmental Medicine 2004;15(3):198‐201. [PUBMED: 15473460] - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version access August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995‐8. [PUBMED: 18456631] - PMC - PubMed
Hackett 1988
    1. Hackett PH, Roach RC, Wood RA, Foutch RG, Meehan RT, Rennie D, et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviation, Space, and Environmental Medicine 1988;59(10):950‐4. [PUBMED: 3190622] - PubMed
Hackett 1992
    1. Hackett PH, Roach RC, Hartig GS, Greene ER, Levine BD. The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. International Journal of Sports Medicine 1992;13 Suppl 1:68‐71. [PUBMED: 1483798] - PubMed
Hackett 2004
    1. Hackett PH, Roach RC. High altitude cerebral edema. High Altitude Medicine & Biology 2004;5(2):136‐46. [PUBMED: 15265335] - PubMed
Hall 2011
    1. Hall DP, Duncan K, Baillie JK. High altitude pulmonary oedema. Journal of the Royal Army Medical Corps 2011;157(1):68‐72. [PUBMED: 21465914] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [PUBMED: 12958120] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hill 1909
    1. Hill L. An oxygen generator and inhaler: its use in mountain sickness. British Medical Journal 1909;2(2552):1522‐4. [PUBMED: 20764764] - PMC - PubMed
Hultgren 1975
    1. Hultgren HN. Letter: Furosemide for high altitude pulmonary edema. JAMA 1975;234(6):589‐90. [PUBMED: 1242183] - PubMed
Höhne 2007
    1. Höhne C, Pickerodt PA, Francis RC, Boemke W, Swenson ER. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. American Journal of Physiology. Lung Cellular and Molecular Physiology 2007;292(1):L178‐84. [PUBMED: 16936246] - PubMed
Imray 2010
    1. Imray C, Wright A, Subudhi A, Roach R. Acute mountain sickness: pathophysiology, prevention, and treatment. Progress in Cardiovascular Diseases 2010;52(6):467‐84. [PUBMED: 20417340] - PubMed
Jafarian 2007b
    1. Jafarian S, Gorouhi F, Salimi S, Lotfi J. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Annals of Neurology 2007;62(3):273‐7. [PUBMED: 17557349] - PubMed
Koch 2009
    1. Koch RO, Hinterhuber L, Faulhaber M, Gatterer H, Graupner S, Muenzel K, et al. A successful therapy of high‐altitude pulmonary edema with a CPAP helmet on Lenin Peak. Clinical Journal of Sport Medicine 2009;19(1):72‐3. [PUBMED: 19124989] - PubMed
Larson 1992
    1. Larson EB. Positive airway pressure for high‐altitude pulmonary oedema. Lancet 1985;1(8425):371‐3. [PUBMED: 2857423] - PubMed
Leaf 2007
    1. Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. Journal of Applied Physiology 2007; Vol. 102, issue 4:1313‐22. [PUBMED: 17023566] - PubMed
Leissner 2009
    1. Leissner KB, Mahmood FU. Physiology and pathophysiology at high altitude: considerations for the anesthesiologist. Journal of Anesthesia 2009;23(4):543‐53. [PUBMED: 19921365] - PubMed
León‐Velarde 2010
    1. León‐Velarde F, Villafuerte FC, Richalet JP. Chronic mountain sickness and the heart. Progress in Cardiovascular Diseases 2010;52(6):540‐9. [PUBMED: 20417348] - PubMed
Luks 2010
    1. Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness & Environmental Medicine 2010;21(2):146‐55. [PUBMED: 20591379] - PubMed
Luks 2014
    1. Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness & Environmental Medicine 2014;25(4 Suppl):S4‐14. [PUBMED: 25498261] - PubMed
Luks 2017
    1. Luks AM, Swenson ER, Bartsch P. Acute high‐altitude sickness. European Respiratory Review 2017;26(143):1‐14. [PUBMED: 28143879] - PMC - PubMed
Maggiorini 2010
    1. Maggiorini M. Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases 2010;52(6):500‐6. [PUBMED: 20417343] - PubMed
Maneuf 2006
    1. Maneuf YP, Luo ZD, Lee K. Alpha2 delta and the mechanism of action of gabapentin in the treatment of pain. Seminars in Cell & Developmental Biology 2006;17(5):565‐70. [PUBMED: 17067834] - PubMed
Monge 1942
    1. Monge C. Life in the Andes and chronic mountain sickness. Science (New York, N.Y.) 1942;95(2456):79‐84. [PUBMED: 17757318] - PubMed
Murata 2004
    1. Murata T, Hori M, Sakamoto K, Karaki H, Ozaki H. Dexamethasone blocks hypoxia‐induced endothelial dysfunction in organ‐cultured pulmonary arteries. American Journal of Respiratory and Critical Care Medicine 2004;170(6):647‐55. [PUBMED: 15184203] - PubMed
Murata 2005
    1. Murata T, Suzuki N, Yamawaki H, Sato K, Hori M, Karaki H, et al. Dexamethasone prevents impairment of endothelium‐dependent relaxation in arteries cultured with fetal bovine serum. European Journal of Pharmacology 2005;515(1‐3):134‐41. [PUBMED: 15907323] - PubMed
Murdoch 2010
    1. Murdoch D. Altitude sickness. BMJ Clinical Evidence 2010;2010:1209. [PUBMED: 21718562] - PMC - PubMed
Nebeker 2004
    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795‐801. [PUBMED: 15148066] - PubMed
Nieto Estrada 2017
    1. Nieto Estrada VH, Molano Franco D, Medina RD, Gonzalez Garay AG, Martí‐Carvajal AJ, Arevalo‐Rodriguez I. Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs. Cochrane Database of Systematic Reviews 2017, Issue 6. [DOI: 10.1002/14651858.CD009761.pub2] - DOI - PMC - PubMed
Palmer 2010
    1. Palmer BF. Physiology and pathophysiology with ascent to altitude. American Journal of the Medical Sciences 2010;340(1):69‐77. [PUBMED: 20442648] - PubMed
Paralikar 2010
    1. Paralikar SJ, Paralikar JH. High‐altitude medicine. Indian Journal of Occupational and Environmental Medicine 2010;14(1):6‐12. [PUBMED: 20808661] - PMC - PubMed
Pasha 2010
    1. Pasha MA, Newman JH. High‐altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010;137 Suppl 6:13‐9. [PUBMED: 20522576] - PubMed
Pattinson 2005
    1. Pattinson KT, Somogyi RB, Fisher JA, Bradwell AR. Efficient breathing circuit for use at altitude. Wilderness & Environmental Medicine 2005;16(2):101‐3. [PUBMED: 15974260] - PubMed
Porta 2008
    1. Porta M. A Dictionary of Epidemiology. 5th Edition. London: Oxford University Press, 2008.
Pubchem ‐ Furosemide 2017
    1. National Center for Biotechnology Information ‒ Pubchem: Open Chemistry Database. Furosemide C12H11ClN2O5S ‐ Compound summary for CID 3440 [Internet]. pubchem.ncbi.nlm.nih.gov/compound/furosemide [cited 20 February 2017].
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ri‐Li 2003
    1. Ri‐Li G, Chase PJ, Witkowski S, Wyrick BL, Stone JA, Levine BD, et al. Obesity: associations with acute mountain sickness. Annals of Internal Medicine 2003;139(4):253‐7. [PUBMED: 12965980] - PubMed
Roach 1993
    1. Roach RC, Bärtsch P, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. In: Surron JR, Houston CS, Coates G editor(s). Hypoxia and Molecular Medicine. Burlington: Queen City Printers Inc., 1993:272‐4.
Sampson 1983
    1. Sampson JB, Cymerman A, Burse RL, Maher JT, Rock PB. Procedures for the measurement of acute mountain sickness. Aviation, Space, and Environmental Medicine 1983;54(12 Pt 1):1063‐73. [PUBMED: 6661120] - PubMed
Scherrer 1996
    1. Scherrer U, Vollenweider L, Delabays A, Savcic M, Eichenberger U, Kleger GR, et al. Inhaled nitric oxide for high‐altitude pulmonary edema. New England Journal of Medicine 1996;334(10):624‐9. [PUBMED: 8592525] - PubMed
Scherrer 2010
    1. Scherrer U, Rexhaj E, Jayet PY, Allemann Y, Sartori C. New insights in the pathogenesis of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases 2010;52(6):485‐92. [PUBMED: 20417341] - PubMed
Schoene 1985
    1. Schoene RB, Roach RC, Hackett PH, Harrison G, Mills WJ Jr. High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley. Effect of expiratory positive airway pressure. Chest 1985;87(3):330‐3. [PUBMED: 3882350] - PubMed
Schoene 2004
    1. Schoene RB. Unraveling the mechanism of high altitude pulmonary edema. High Altitude Medicine & Biology 2004;5(2):125‐35. [PUBMED: 15265334] - PubMed
Schoene 2008
    1. Schoene RB. Illnesses at high altitude. Chest 2008;134(2):402‐16. [PUBMED: 18682459] - PubMed
Seupaul 2012
    1. Seupaul RA, Welch JL, Malka ST, Emmett TW. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Annals of Emergency Medicine 2012;59(4):307‐17.e1. [PUBMED: 22153998] - PubMed
Smedley 2013
    1. Smedley T, Grocott MP. Acute high‐altitude illness: a clinically orientated review. British Journal of Pain 2013;7(2):85‐94. [PUBMED: 26516505] - PMC - PubMed
Stream 2008
    1. Stream JO, Grissom CK. Update on high‐altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness & Environmental Medicine 2008;19(4):293‐303. [PUBMED: 19099331] - PubMed
Tang 2014
    1. Tang E, Chen Y, Luo Y. Dexamethasone for the prevention of acute mountain sickness: systematic review and meta‐analysis. International Journal of Cardiology 2014;173(2):133‐8. [PUBMED: 24679688] - PubMed
Wang 2003
    1. Wang T, Kebir D, Blaise G. Inhaled nitric oxide in 2003: a review of its mechanisms of action. Canadian Journal of Anaesthesia/Journal canadien d'anesthésie 2003;50(8):839‐46. [PUBMED: 14525827] - PubMed
Windsor 2009
    1. Windsor JS, Firth PG, Grocott MP, Rodway GW, Montgomery HE. Mountain mortality: a review of deaths that occur during recreational activities in the mountains. Postgraduate Medical Journal 2009;85(1004):316‐21. [PUBMED: 19528307] - PubMed
Wright 2004
    1. Wright AD, Beazley MF, Bradwell AR, Chesner IM, Clayton RN, Forster PJ, et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness & Environmental Medicine 2004;15(1):25‐31. [PUBMED: 15040503] - PubMed
Wright 2008
    1. Wright A, Brearey S, Imray C. High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high‐altitude cerebral and pulmonary oedema. Expert Opinion on Pharmacotherapy 2008;9(1):119‐27. [PUBMED: 18076343] - PubMed
Xu 2014
    1. Xu Y, Liu Y, Liu J, Qian G. Meta‐analysis of clinical efficacy of sildenafil, a phosphodiesterase type‐5 inhibitor on high altitude hypoxia and its complications. High Altitude Medicine & Biology 2014;15(1):46‐51. [PUBMED: 24673534] - PubMed
Yang 2007
    1. Yang B, Wang GY, Chen B, Qin RB, Xi SL, Chen L. Anti‐hypoxia and anti‐oxidation effects of aminophylline on human with acute high‐altitude exposure. Chinese Medical Sciences Journal 2007;22(1):62‐5. [PUBMED: 17441321] - PubMed
Zafren 1996
    1. Zafren K, Reeves JT, Schoene R. Treatment of high‐altitude pulmonary edema by bed rest and supplemental oxygen. Wilderness & Environmental Medicine 1996;7(2):127‐32. [PUBMED: 11990106] - PubMed
Zafren 1998
    1. Zafren K. Gamow bag for high‐altitude cerebral oedema. Lancet 1998; Vol. 352, issue 9124:325‐6. [PUBMED: 9690443] - PubMed

References to other published versions of this review

Martí‐Carvajal 2012
    1. Martí‐Carvajal AJ, Simancas‐Racines D, Hidalgo R. Interventions for treating high altitude illness. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD009567] - DOI - PubMed

Publication types

Supplementary concepts

LinkOut - more resources